Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Androgen deprivation therapy does not keep localized prostate cancer from spreading, new study says

27.02.2006


Hormonal treatment gaining popularity for localized prostate cancer despite little understanding of its effectiveness

Oregon Health & Science University Cancer Institute researchers wanted to know if depriving men of testosterone actually keeps cancer from spreading beyond the prostate. What they found is that men who have localized prostate cancer with certain high-risk features and receive this treatment -- known as androgen deprivation therapy -- remain at risk of dying from prostate cancer.

"The notion that androgen deprivation therapy will hold prostate cancer at bay while you die of something else is not proving to be entirely true," said Tomasz Beer, M.D., director of the Prostate Cancer Research Program in the Oregon Health & Science University Cancer Institute.



This is especially important because recent studies of physician practice trends show that androgen deprivation therapy is being used with increased frequency for men with prostate cancer that has not spread.

"Reasons for this trend are not really known, but may include a desire to do something rather than do nothing on the part of both physicians and patients," Beer said. "Unfortunately, these men may be enduring significant side effects for an uncertain benefit."

Androgen deprivation therapy, also known as hormone therapy, is the gold standard of care for men whose prostate cancer is advanced and has spread throughout the body. The therapy works by shutting down male hormones, principally testosterone, that can promote prostate cancer growth. This common treatment for prostate cancer wipes out most male hormones found in the body. Side effects can be significant and include erectile dysfunction, hot flashes, fatigue, osteoporosis, high cholesterol, anemia, forgetfulness and insomnia.

Little is known about the effectiveness of hormonal therapy in men whose cancer remains localized within the prostate, so Beer and his colleagues decided to study data from the Prostate Cancer Outcome Study (PCOS). They presented their results on Saturday, Feb. 25, at the Prostate Cancer Symposium in San Francisco.

In the retrospective study, the research team examined demographic data, socio-economic factors and tumor biology in relationship to overall survival and cancer-specific survival for a subgroup of 276 PCOS subjects who had localized prostate cancer and received androgen deprivation therapy as their primary treatment. Between 1994 and 1995, a total of 3,486 men were enrolled in PCOS within six months of prostate cancer diagnosis.

The analysis showed that out all the demographic and socio-economic factors considered, overall survival was predicted only by age and certain features of prostate cancer. Tumor biology, which is measured by Gleason score, was the only independent predictor of cancer specific survival. Tumor mass as measured by PSA approached statistical significance as a predictor. Nearly 10 percent of men died from prostate cancer within 5 years of starting hormonal therapy.

"Our study indicates that cancer remains an important contributor to overall mortality in these men, particularly those with high Gleason score and high serum PSA," Beer said. "These data will be useful for men with localized prostate cancer choosing between aggressive treatments such as surgery or radiation, observation and androgen deprivation therapy."

In an earlier OHSU Cancer Institute study of the effectiveness of hormone deprivation as a primary therapy for localized prostate cancer, researchers found that younger men and those with higher-grade tumors are more likely to experience disease progression during treatment. They also found that men with localized prostate cancer on hormone therapy experience a higher than expected rate of bone fractures caused primarily by treatment-related osteoporosis.

"Studies suggest that more needs to be known about the risks and benefits of this treatment before we recommend it to patients with localized disease," Beer said.

Prostate cancer is the most common cancer in men and the second leading cause of cancer-related death in American men. Overall, 1 in 6 men will develop prostate cancer during his lifetime.

Rachel MacKnight | EurekAlert!
Further information:
http://www.ohsu.edu

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>